Epithelioid sarcoma · line 1 · Tazemetostat monotherapy (advanced epithelioid sarcoma, SMARCB1/INI1-deficient)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-TAZEMETOSTAT-EPITHELIOID-SARCOMA |
| ID | IND-EPITHELIOID-SARCOMA-1L-TAZEMETOSTAT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-EPITHELIOID-SARCOMA |
| Sources | SRC-ESMO-SARCOMA-2024 SRC-EZH202-GOUNDER-2020 |
Notes
STUB — pending Clinical Co-Lead sign-off. Only FDA-approved targeted therapy for epithelioid sarcoma. ORR modest (~15%) but clinically meaningful given no prior options. SMARCB1/INI1 IHC required before prescribing. Access in Ukraine via DEC named-patient import or EAP Ipsen.
Used By
Algorithms
ALGO-EPITHELIOID-SARCOMA-1L- ALGO-EPITHELIOID-SARCOMA-1L